SEC Form 4 · accession 0001104659-16-123688
STEMLINE THERAPEUTICS INC · STML
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth J Zuerblis
Director
Period of report
May 25, 2016
Accepted (ET)
May 26, 2016 · 4:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001264587
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F1 | $6.78 | May 25, 2016 | A | 34,000 | A | May 25, 2017 | May 25, 2026 | Common Stock | 34,000 | 34,000 | D |
Explanation of responses
- F1The options will vest according to the following schedule: one-third on each of 5/25/2017, 5/25/2018, and 5/25/2019.